SAN FRANCISCO, Jan. 23, 2019 /PRNewswire/ -- The One Health Company, a Silicon Valley-based startup whose mission is to make canine cancer treatment more accessible and affordable, today announced they raised a $5M seed round led by Andreessen Horowitz's Bio fund, with participation from Lerer Hippeau and Y Combinator. Dr. Amy Abernathy, a founding advisor for One Health, was recently nominated to be the deputy commissioner of the FDA.
"At One Health, we're committed to advancing veterinary medicine and helping our beloved dogs live longer, healthier and happier lives," said One Health founder and CEO Christina Lopes. "By using the same diagnostics, machine learning rules, and drugs that are currently on the market for people, we're able to provide pet parents with cutting-edge cancer treatments at an affordable cost."
More than 90 million dogs are living in U.S. households, and an estimated one out of five of them will develop cancer at some point in their lives. One Health is the first company to bring next-generation sequencing to veterinary cancer. FidoCure, One Health's flagship product, allows users to purchase treatment plans for a fixed price and have access to the world's leading canine cancer care.
How FidoCure works:
About The One Health CompanyThe One Health Company is the first to bring the latest advances in human oncology to dogs with cancer. We deliver the most sophisticated diagnostics and create a tailored treatment for each dog. Visit theonehealthcompany.com.
Advertisement
"At One Health, we're committed to advancing veterinary medicine and helping our beloved dogs live longer, healthier and happier lives," said One Health founder and CEO Christina Lopes. "By using the same diagnostics, machine learning rules, and drugs that are currently on the market for people, we're able to provide pet parents with cutting-edge cancer treatments at an affordable cost."
Advertisement
More than 90 million dogs are living in U.S. households, and an estimated one out of five of them will develop cancer at some point in their lives. One Health is the first company to bring next-generation sequencing to veterinary cancer. FidoCure, One Health's flagship product, allows users to purchase treatment plans for a fixed price and have access to the world's leading canine cancer care.
How FidoCure works:
- Genetic Testing: One Health uses gene sequencing to understand the exact genetic mutation that is causing your dog's cancer.
- Action Plan: Users receive recommendations to help understand what is driving their dog's cancer and the best therapeutic implications.
- Treatment: Genetic sequencing results are used to provide individualized, targeted treatment leveraging the latest science available in oncology.
About The One Health CompanyThe One Health Company is the first to bring the latest advances in human oncology to dogs with cancer. We deliver the most sophisticated diagnostics and create a tailored treatment for each dog. Visit theonehealthcompany.com.
View original content:http://www.prnewswire.com/news-releases/one-health-raises-5m-to-make-dog-cancer-treatment-more-accessible-and-affordable-300782813.html
SOURCE The One Health Company